November 12–14, 2010
Hilton Munich City, Munich, Germany
Register now!
Attendance is limited to 75 participants to ensure the optimal instructor/student ratio and quality interaction.
Take your skills to the next level by working
directly with colleagues in a hands-on, practical course
that uses a realistic business case!
The Advanced Business Development Course is designed
for business development professionals interested in bringing
their skills in valuation, due diligence, negotiation
and contracts to the next level. During this intense,
three-day session attendees will receive hands-on, advanced
training from veteran business development professionals
and legal advisers using real-world case studies. In addition,
attendees will be split into two teams to conduct a mock
negotiation over a clinical stage compound.
Since 2004, this course has been organized for life science business development professionals by the Biotechnology Industry Organization in collaboration with EBD Group. The faculty is drawn from among the most experienced business development professionals in the biotech drug development industry as well as big pharma, many of whom have been instructors in other programs, and all of whom have extensive experience in the biotech industry.
The course will cover basic topics and skills crucial
to every business development professional in the industry,
including:
- Valuation skills
- Intellectual property
- Due diligence
- Negotiation and influence strategies
Who should attend?
Although this course is recommended for business development
professionals with approximately 3–5 years experience,
people with less experience have taken it and benefited
a great deal. It is designed for business development
professionals who have most likely served as part of a
business development or licensing team, but are now preparing
to move to a senior manager role within their organization.
- Business development and licensing professionals
- Alliance management professionals
- R&D personnel who have significant interaction
with business development
- Intellectual property personnel involved in the licensing
process
- Biotech company CEOs
Attendance is limited to 75 participants to ensure
the optimal instructor/student ratio and quality interaction.
 |
And stay for the BIO-Europe
2010 international partnering conference,
which starts immediately after this course finishes.
|
|
